In the last years, there is great impetus to discover new biomarkers in RCC in order to address the patients toward an
appropriate adjuvant therapy. In this regard, miR501-5p that is differentially expressed in RCC and mTOR which in many
tumours correlates with a poor prognosis, could represent possible biomarkers. Therefore, miR501-5p expression and
mTOR activity will be studied in normal and RCC tissues as well as in kidney cell lines depleted or enriched in miR501-5p
sequences.
Cell growth, apoptosis, autophagy and related signaling pathways will be analyzed in kidney cells and tissues expressing
different levels of miR501-5p in order to evaluate the role of miR501-5p in RCC.
High and low miR501-5p expression levels combined with mTOR activity of different RCC tissues will be matched with the
outcome of RCC patients to evaluate their possible prognostic role
